Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 13, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

April 21, 2021

Conditions
Peripheral T Cell LymphomaPTCLExtranodal NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeExtranodal NK T Cell LymphomaExtranodal NK T Cell Lymphoma, NasalAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaAngioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma RefractoryPeripheral T-cell Lymphoma NOSPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T-Cell Lymphoma RefractoryAnaplastic Large Cell LymphomaAnaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-negativeALK-negative Anaplastic Large Cell LymphomaALK-Positive Anaplastic Large Cell LymphomaCutaneous T-cell Lymphoma
Interventions
DRUG

Tislelizumab

Administered intravenously

Trial Locations (24)

10048

National Taiwan University Hospital, Taipei

14033

Institut Dhematologie de Basse Normandie Chu Caen Normandie, Caen

16121

Ospedale Policlinico San Martino Irccs Per L Oncologia, Divisione Ematologia Centro Trapianti Di Mid, Genova

20132

Ospedale San Raffaele, Milan

24127

Asst Papa Giovanni Xxiii, Medicina Trasfusionale Ed Ematologia, Bergamo

40138

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna

43126

Ospedale Maggiore, Ematologia E Centro Trapianti Midollo Osseo (Ctmo), Aou Parma, Parma

56126

Aou Pisana, Stabilimento Di Santa Chiara, Pisa

69495

Chu Hopital Lyon Sud, PierreBenite

100000

Peking University Third Hospital, Beijing

100730

Beijing Hospital, Beijing

Peking Union Medical College Hospital, Beijing

150000

Harbin Medical University Cancer Hospital, Harbin

200000

Fudan University Shanghai Cancer Center, Shanghai

200092

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Hangzhou

350001

Fujian Medical University Union Hospital, Fuzhou

450000

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat Sen University Cancer Center, Guangzhou

610041

West China Hospital, Sichuan University, Chengdu

V5Z 4E6

British Columbia Cancer Agency the Vancouver Centre, Vancouver

05100

Azienda Ospedaliera S Maria Di Terni, Terni

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | Biotech Hunter | Biotech Hunter